Skip to main content

Table 5 Assessment of test beverage influence on post trial DALDA questionnaire and subjective muscle soreness

From: An investigative study into the influence of a commercially available carbohydrate-protein-electrolyte beverage on short term repeated exercise performance

  

PL

  

CPE

 
 

P1

P2

P3

P1

P2

P3

DALDA Part A

1.46 ± 0.39

1.08 ± 0.33

0.85 ± 0.27

1.00 ± 0.30

1.15 ± 0.30

1.08 ± 0.24

DALDA Part B

3.08 ± 0.76

3.15 ± 0.94

1.92 ± 0.74

3.23 ± 0.65

2.15 ± 0.59

1.77 ± 0.30

MQS

2.21 ± 0.35

1.65 ± 0.20

1.49 ± 0.16

1.68 ± 0.21

1.36 ± 0.14

1.28 ± 0.15*

MVLS

2.27 ± 0.38

1.62 ± 0.21

1.50 ± 0.16

1.65 ± 0.22

1.35 ± 0.15

1.19 ± 0.13*#

MDVLS

2.31 ± 0.35

1.54 ± 0.18

1.46 ± 0.14

1.69 ± 0.26

1.31 ± 0.17

1.15 ± 0.10*#

MHS

2.15 ± 0.33

1.69 ± 0.21

1.35 ± 0.13

1.73 ± 0.31

1.58 ± 0.30

1.42 ± 0.21

  1. Values are presented as mean ± SE; n = 16; PL, Placebo; CPE, carbohydrate-protein-electrolyte; P1-3, post trial days 1 to 3; MQS, mean quadriceps soreness; MVLS, mean vastus lateralis soreness; MDVLS, mean distal vastus lateralis soreness; MHS, mean hamstring soreness.* denotes a significant reduction between P1 and P3 overall (P < 0.05). # denotes a significant reduction between P1 and P2 overall (P < 0.05).